Healthcare Jan 25, 2022 05:26 PM (GMT+8) · EqualOcean
Yiouda health learned on the 25th that Tongxin medical announced that it had recently completed a round of D + financing of hundreds of millions of yuan. This round of financing was jointly led by CICC Qide, PICC capital, Honghui fund and old shareholder Lingdao capital. The existing shareholders Sequoia China, Qingchi capital and houxin health investment continued to make additional investment, with the joint participation of Jingming capital and Guozhu capital. This round of financing funds will be used to accelerate the self-developed implantable ventricular assist device ch-vad based on the full magnetic levitation technology route of concentric medicine ® The commercialization process in China promotes the establishment and improvement of ventricular assist device (VAD) therapy in China; At the same time, it will also be further used in the overseas clinical layout of concentric medicine. Tongxin medical was founded in 2008 by a team of overseas scientific and technological experts. It focuses on the research and development of the world's leading ventricular assist device (artificial heart) and promotes the commercialization and sales of artificial heart all over the world. Ch-vad independently developed by the company ® Implantable left ventricular assist system was approved by the State Drug Administration (nmpa) in November 2021. It is the first VAD with complete independent intellectual property rights approved by nmpa in China and the first full magnetic levitation VAD approved by nmpa in the world.